Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764953 | 0.88 | NPC1 (0.49) | NPC1POLBRAB9AHPGDTP53 | |
| SCHEMBL9112546 | 0.84 | ABCG2 (0.49) | NPC1POLBABCG2RAB9AHPGD | |
| SCHEMBL7200630 | 0.84 | NPC1 (0.53) | NPC1POLBABCG2RAB9ACTSD | |
| SCHEMBL8146118 | 0.82 | TUBB1 (0.52) | NPC1POLBABCG2RAB9AHPGD | |
| SCHEMBL4864056 | 0.82 | TUBB1 (0.49) | NPC1POLBABCG2RAB9AALDH1A1 | |
| SCHEMBL7195261 | 0.82 | CYP3A4 (0.47) | NPC1POLBABCG2RAB9ACTSD | |
| SCHEMBL11296303 | 0.81 | SMN1; SMN2 (0.58) | NPC1POLBRAB9AHPGDALDH1A1 | |
| SCHEMBL728021 | 0.80 | ABCG2 (0.51) | POLBABCG2HPGDCA1CA2 | |
| SCHEMBL6129273 | 0.80 | ABCG2 (0.51) | POLBABCG2HPGDCA1CA2 | |
| SCHEMBL19183066 | 0.79 | TUBB1 (0.45) | NPC1POLBABCG2GLASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| WO-2023165870-A1 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS ON BONE HEALTH | Société des Produits Nestlé S.A. (CH) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023158383-A2 | METHOD FOR CELLULAR LIFESPAN MEASUREMENT | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-08-24 | — | — | WO | disclosed |
| EP-2810198-B1 | ANTI-INVASIVE COMPOUNDS | UNIV GENT (BE) | 2023-07-12 | — | — | EP | disclosed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| EP-3986557-A1 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS | Société des Produits Nestlé S.A. (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2022-03-08 | — | — | US | disclosed |
| WO-2020254664-A1 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS | Société des Produits Nestlé S.A. (CH) | 2020-12-24 | — | — | WO | disclosed |
| EP-1781305-A2 | COMPOSITIONS AND METHODS USING HYALURONIC ACID AND HYALURONIDASE INHIBITORS | ANGIOTECH INTERNATIONAL AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| EP-1748767-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | Unigen Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006020994-A2 | COMPOSITIONS AND METHODS USING HYALURONIC ACID AND HYLURONIDASE INHIBITORS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| EP-0661967-A1 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1995-07-12 | — | — | EP | disclosed |
| EP-0661967-A4 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS. | UNIV VIRGINIA (US) | 1994-09-29 | — | — | EP | disclosed |
| WO-1993009764-A1 | COMBINED VIRUSTATIC ANTIMEDIATOR (COVAM) TREATMENT OF COMMON COLDS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-05-27 | — | — | WO | disclosed |
| US-4863968-A | Methods of treating gout with chalcone derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | HNMT, INMT, TYR | NPC1 2485/4885POLB 1598/4885ABCG2 2175/4885 |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | MCL1, CD44, INMT | NPC1 518/4885POLB 3395/4885ABCG2 1523/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | NPC1 926/4885POLB 2971/4885ABCG2 1341/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | NPC1 1134/4885POLB 1937/4885ABCG2 535/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NPC1 1517/4885POLB 1803/4885ABCG2 842/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | NPC1 2233/4885POLB 2225/4885ABCG2 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.